FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205207841> ?p ?o ?g. }

• W3205207841 abstract "The prognosis for female patients with locally advanced breast cancer (LABC) has improved with the emergence of novel drugs, especially for those who have HER2 overexpression or ERBB-2 amplification. Trastuzumab-based regimen has been the paradigm in guidelines as first-line therapy, whereas many patients got progressive disease after several cycles of treatment or rapidly progress because of primary resistance. Point mutations of ERBB2 gene occur in both HER2-amplication and non-amplification patients, with a 2% ratio in HER2 non-amplification cohort and 1.48% in HER2 amplication population. The acquired mutation ratio of ERBB2 substantially raised to 16.7%-17.7% in patients prior to trastuzumab treatment. ERBB2 mutation may be a critical reason of resistance and disease progression among the patients treated with anti-HER2 monoclonal trastuzumab or dual anti-HER2 antibodies with trastuzumab and pertuzumab, or tyrosine-kinase inhibitor. ERBB-2 mutation with L755S and V842I indicates resistance to trastuzumab, while that with L755S and K753I indicates resistance to lapatinib; these mutations maybe sensitive to pan-HER tyrosine-kinase inhibitors. A 48-year woman diagnosed with HER2-positive LABC developed trastuzumab resistance after three lines of trastuzumab cross-line treatment with partial response (PR) as the best response. The tissue was performed by next-generation sequencing (NGS), and the results discovered L755S in ERBB2 gene. Then, she received effective treatment with pyrotinib plus capecitabine and underwent mastectomy after six cycles of combined treatment with PR. Subsequently, breast mastectomy was performed, and she took pyrotinib plus capecitabine for 1 year and pyrotinib monotherapy for another 1 year as adjuvant therapy and achieved a long-term clinical benefit. In conclusion, pyrotinib is a potential neoadjuvant agent for patients who are heavily pretreated and harbor both ERBB2 amplification and ERBB2 mutant in locally advanced breast cancer." @default.
• W3205207841 created "2021-10-25" @default.
• W3205207841 creator A5000292982 @default.
• W3205207841 creator A5032600833 @default.
• W3205207841 creator A5056948476 @default.
• W3205207841 creator A5061832044 @default.
• W3205207841 creator A5086885652 @default.
• W3205207841 date "2021-10-14" @default.
• W3205207841 modified "2023-10-10" @default.
• W3205207841 title "Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant" @default.
• W3205207841 cites W1830454849 @default.
• W3205207841 cites W1964808503 @default.
• W3205207841 cites W1969380159 @default.
• W3205207841 cites W1985213644 @default.
• W3205207841 cites W1987326983 @default.
• W3205207841 cites W2019388333 @default.
• W3205207841 cites W2022678011 @default.
• W3205207841 cites W2095659509 @default.
• W3205207841 cites W2101299592 @default.
• W3205207841 cites W2103678314 @default.
• W3205207841 cites W2110444464 @default.
• W3205207841 cites W2120627364 @default.
• W3205207841 cites W2127714324 @default.
• W3205207841 cites W2137086207 @default.
• W3205207841 cites W2149719146 @default.
• W3205207841 cites W2149773268 @default.
• W3205207841 cites W2170241131 @default.
• W3205207841 cites W2172118845 @default.
• W3205207841 cites W2195054423 @default.
• W3205207841 cites W2195827035 @default.
• W3205207841 cites W2529854314 @default.
• W3205207841 cites W2613098450 @default.
• W3205207841 cites W2613784923 @default.
• W3205207841 cites W2616596696 @default.
• W3205207841 cites W2770503852 @default.
• W3205207841 cites W2785610956 @default.
• W3205207841 cites W2804104844 @default.
• W3205207841 cites W2895955393 @default.
• W3205207841 cites W2918943485 @default.
• W3205207841 cites W2945384827 @default.
• W3205207841 cites W2947067095 @default.
• W3205207841 cites W2969604985 @default.
• W3205207841 cites W2996630100 @default.
• W3205207841 cites W3009593680 @default.
• W3205207841 cites W3092280067 @default.
• W3205207841 cites W3123743675 @default.
• W3205207841 cites W3127064904 @default.
• W3205207841 cites W3142570532 @default.
• W3205207841 cites W4211032970 @default.
• W3205207841 cites W4239989216 @default.
• W3205207841 cites W4241868283 @default.
• W3205207841 doi "https://doi.org/10.3389/fonc.2021.715554" @default.
• W3205207841 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8553255" @default.
• W3205207841 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34722261" @default.
• W3205207841 hasPublicationYear "2021" @default.
• W3205207841 type Work @default.
• W3205207841 sameAs 3205207841 @default.
• W3205207841 citedByCount "3" @default.
• W3205207841 countsByYear W32052078412021 @default.
• W3205207841 countsByYear W32052078412022 @default.
• W3205207841 countsByYear W32052078412023 @default.
• W3205207841 crossrefType "journal-article" @default.
• W3205207841 hasAuthorship W3205207841A5000292982 @default.
• W3205207841 hasAuthorship W3205207841A5032600833 @default.
• W3205207841 hasAuthorship W3205207841A5056948476 @default.
• W3205207841 hasAuthorship W3205207841A5061832044 @default.
• W3205207841 hasAuthorship W3205207841A5086885652 @default.
• W3205207841 hasBestOaLocation W32052078411 @default.
• W3205207841 hasConcept C121608353 @default.
• W3205207841 hasConcept C126322002 @default.
• W3205207841 hasConcept C143998085 @default.
• W3205207841 hasConcept C2777329042 @default.
• W3205207841 hasConcept C2777909004 @default.
• W3205207841 hasConcept C2777930144 @default.
• W3205207841 hasConcept C2779251935 @default.
• W3205207841 hasConcept C2779786085 @default.
• W3205207841 hasConcept C2781187634 @default.
• W3205207841 hasConcept C2781413609 @default.
• W3205207841 hasConcept C502942594 @default.
• W3205207841 hasConcept C526805850 @default.
• W3205207841 hasConcept C530470458 @default.
• W3205207841 hasConcept C71924100 @default.
• W3205207841 hasConceptScore W3205207841C121608353 @default.
• W3205207841 hasConceptScore W3205207841C126322002 @default.
• W3205207841 hasConceptScore W3205207841C143998085 @default.
• W3205207841 hasConceptScore W3205207841C2777329042 @default.
• W3205207841 hasConceptScore W3205207841C2777909004 @default.
• W3205207841 hasConceptScore W3205207841C2777930144 @default.
• W3205207841 hasConceptScore W3205207841C2779251935 @default.
• W3205207841 hasConceptScore W3205207841C2779786085 @default.
• W3205207841 hasConceptScore W3205207841C2781187634 @default.
• W3205207841 hasConceptScore W3205207841C2781413609 @default.
• W3205207841 hasConceptScore W3205207841C502942594 @default.
• W3205207841 hasConceptScore W3205207841C526805850 @default.
• W3205207841 hasConceptScore W3205207841C530470458 @default.
• W3205207841 hasConceptScore W3205207841C71924100 @default.
• W3205207841 hasFunder F4320326042 @default.
• W3205207841 hasFunder F4320329895 @default.
• W3205207841 hasLocation W32052078411 @default.
• W3205207841 hasLocation W32052078412 @default.

• next